Literature DB >> 33531081

Lack of correlation of Brucella antibody titers with clinical outcomes and culture positivity of brucellosis.

Shahad A Alsubaie1, Shouq A Turkistani1, Alanoud A Zeaiter1, Abrar K Thabit2.   

Abstract

BACKGROUND: Brucellosis is a zoonotic disease caused by Brucella spp., namely B. melitensis and B. abortus in humans. Culturing is the gold standard method for diagnosis; however, because Brucella is a slow-growing bacterium, which may delay diagnosis, other faster methods, such as serology, are used. Studies on the correlation between Brucella antibody titers and clinical outcomes are limited. Therefore, this study assessed such correlation and evaluated the correlation between baseline serological results with culture positivity and clinical picture.
METHODS: Patients tested positive for Brucella antibodies at baseline and diagnosed with brucellosis between January 2008 and December 2018 were included. Collected data included clinical outcomes, baseline culture positivity (growth in culture), arthralgia, baseline and end of therapy (EOT) temperature, white blood cell count, C-reactive protein level, and erythrocyte sedimentation rate.
RESULTS: Of 695 patients tested for Brucella antibodies, only 94 had positive baseline serology and diagnosed with acute brucellosis, among whom 63 had EOT serology. No significant correlations were found between EOT antibody titers of both Brucella spp. and clinical cure, mortality, length of stay, and duration of therapy. Additionally, no correlations were found between baseline serology and culture positivity, arthralgia, temperature, and other lab values.
CONCLUSION: Brucella serology does not correlate with clinical outcomes at EOT nor with culture positivity at baseline. Therefore, healthcare providers are advised to consider the whole clinical picture of a brucellosis patient without relying solely on serological results during follow up and not replace culturing with serology testing alone at the time of diagnosis.

Entities:  

Keywords:  Antibody; Brucella; Brucellosis; Culture; Serology; Titer

Year:  2021        PMID: 33531081     DOI: 10.1186/s40794-021-00130-w

Source DB:  PubMed          Journal:  Trop Dis Travel Med Vaccines        ISSN: 2055-0936


  9 in total

Review 1.  Update on laboratory diagnosis of human brucellosis.

Authors:  George F Araj
Journal:  Int J Antimicrob Agents       Date:  2010-08-09       Impact factor: 5.283

2.  Guidelines for the management of human brucellosis in the State of Paraná, Brazil.

Authors:  Felipe Francisco Tuon; Natacha Cerchiari; Juliana Clélia Cequinel; Elizabeth El Hajjar Droppa; Suzana Dal Ri Moreira; Tânia Portella Costa; Amanda de Paula Boni Navarro; Antonieta Milleo Handar; Margely Nunes de Souza
Journal:  Rev Soc Bras Med Trop       Date:  2017 Jul-Aug       Impact factor: 1.581

3.  Changes in IgM and IgG antibody concentrations in brucellosis over time: importance for diagnosis and follow-up.

Authors:  E Gazapo; J Gonzalez Lahoz; J L Subiza; M Baquero; J Gil; E G de la Concha
Journal:  J Infect Dis       Date:  1989-02       Impact factor: 5.226

4.  Acute brucellosis in Saudi families: relationship between brucella serology and clinical symptoms.

Authors:  Sara Alsubaie; Maha Almuneef; Mohammed Alshaalan; Hanan Balkhy; Essam Albanyan; Sulaiman Alola; Badria Alotaibi; Ziad A Memish
Journal:  Int J Infect Dis       Date:  2005-07       Impact factor: 3.623

Review 5.  Laboratory-based diagnosis of brucellosis--a review of the literature. Part I: Techniques for direct detection and identification of Brucella spp.

Authors:  Sascha Al Dahouk; Herbert Tomaso; Karsten Nöckler; Heinrich Neubauer; Dimitrios Frangoulidis
Journal:  Clin Lab       Date:  2003       Impact factor: 1.138

Review 6.  Brucellosis in low-income and middle-income countries.

Authors:  Matthew P Rubach; Jo E B Halliday; Sarah Cleaveland; John A Crump
Journal:  Curr Opin Infect Dis       Date:  2013-10       Impact factor: 4.915

7.  Follow-up standard agglutination and 2-mercaptoethanol tests in 175 clinically cured cases of human brucellosis.

Authors:  Mohammad Reza Hasanjani Roushan; Mohammad Jafar Soleimani Amiri; Abolghasem Laly; Amrollah Mostafazadeh; A Bijani
Journal:  Int J Infect Dis       Date:  2009-08-03       Impact factor: 3.623

8.  Utility of Serological Tests in the Era of Molecular Testing for Diagnosis of Human Brucellosis in Endemic Area with Limited Resources.

Authors:  Shashank Purwar; Sharada C Metgud; Manohar B Mutnal; Mahantesh B Nagamoti; Chidanand S Patil
Journal:  J Clin Diagn Res       Date:  2016-02-01

Review 9.  Global burden of human brucellosis: a systematic review of disease frequency.

Authors:  Anna S Dean; Lisa Crump; Helena Greter; Esther Schelling; Jakob Zinsstag
Journal:  PLoS Negl Trop Dis       Date:  2012-10-25
  9 in total
  3 in total

1.  Evidence of co-exposure with Brucella spp, Coxiella burnetii, and Rift Valley fever virus among various species of wildlife in Kenya.

Authors:  Francis Gakuya; James Akoko; Lillian Wambua; Richard Nyamota; Bernard Ronoh; Isaac Lekolool; Athman Mwatondo; Mathew Muturi; Collins Ouma; Daniel Nthiwa; Earl Middlebrook; Jeanne Fair; John Gachohi; Kariuki Njenga; Bernard Bett
Journal:  PLoS Negl Trop Dis       Date:  2022-08-08

2.  Serological Detection of Marine Origin Brucella Exposure in Two Alaska Beluga Stocks.

Authors:  Laura A Thompson; Caroline E C Goertz; Lori T Quakenbush; Kathy Burek Huntington; Robert S Suydam; Raphaela Stimmelmayr; Tracy A Romano
Journal:  Animals (Basel)       Date:  2022-07-29       Impact factor: 3.231

Review 3.  Immunosuppressive Mechanisms in Brucellosis in Light of Chronic Bacterial Diseases.

Authors:  Joaquin Miguel Pellegrini; Jean-Pierre Gorvel; Sylvie Mémet
Journal:  Microorganisms       Date:  2022-06-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.